FDA Alerts (32)

Gilead Asks FDA to Rescind Orphan Drug Status

Updated Story Gilead has asked the US Food and Drug Administration to rescind the orphan drug designation it was granted for remdesivir, an investigational antiviral for the treatment of COVID-19, according to a statement from the company. This would waive all benefits that come along with orphan drug designation, including tax...